Pharma Times
DECEMBER 15, 2020
A new report launched by Takeda has found that just 17% of UK adults surveyed felt their perception of pharma had improved based on the industry's response to COVID-19
NY Times
DECEMBER 15, 2020
The positive review likely ensures that the F.D.A. will grant emergency authorization for a second coronavirus vaccine this week for millions of Americans.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
DECEMBER 17, 2020
Biology 2.0: Combining machine-learning, robotics and biology to deliver drug discovery of tomorrow. Intelligent OMICS, Arctoris and Medicines Discovery Catapult test in silico pipeline for identifying new molecules for cancer treatment. Medicines discovery innovators, Intelligent OMICS, supported by Arctoris and Medicines Discovery Catapult, are applying artificial intelligence to find new disease ‘drivers’ and candidate drugs for lung cancer.
Drug Patent Watch
DECEMBER 17, 2020
Annual Drug Patent Expirations for NUZYRA Nuzyra is a drug marketed by Paratek Pharms Inc and is included in two NDAs. There are ten patents protecting this drug. This drug…. The post New patent for Paratek Pharms drug NUZYRA appeared first on DrugPatentWatch - Make Better Decisions.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharma Times
DECEMBER 15, 2020
The trial is expected to begin next month, with first data anticipated in the second quarter of 2020
NY Times
DECEMBER 15, 2020
The U.S., Britain, Canada and others are hedging their bets, reserving doses that far outnumber their populations, as many poorer nations struggle to secure enough.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Pharma Mirror
DECEMBER 14, 2020
The future of pharmaceutical manufacturing is mobile. Advances in cloud computing and the onset of Industry 4.0 has led to the proliferation of mobile IT solutions for manufacturing, including pharmaceuticals. Particularly, mobile workstations and tablets are becoming staples of the pharmaceutical manufacturing workflow due to their cost-effectiveness, particularly in demanding environments like cleanrooms, where even modular fixed human-machine interfaces (HMIs) can be exorbitantly priced and c
Pharma Times
DECEMBER 14, 2020
The triple combination therapy Trixeo Aerosphere cut the rate of moderate or severe exacerbations compared with dual-combination therapies in clinical trials
NY Times
DECEMBER 17, 2020
Estados Unidos, el Reino Unido, Canadá y otros países hicieron pedidos de vacunas que superan con creces a sus poblaciones, mientras muchas naciones pobres luchan por asegurarse las dosis que necesitan.
pharmaphorum
DECEMBER 14, 2020
The pharma industry has been making great strides forward in digital health, but one element of that – gamification – hasn’t yet made much headway in the sector. Armed with new data from a randomised clinical trial, one company is hoping to change that mindset. The company is FriendsLearn – based in India and with an R&D office in San Francisco – which recently reported results from a trial showing that its fooya!
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Outsourcing Pharma
DECEMBER 16, 2020
The head of the CROâs Global Center of Excellence for Decentralized Clinical Trial Strategy outlines key developments in 2020, and keys to success in 2021.
Pharma Times
DECEMBER 17, 2020
Study will enrol hospitalised COVID-19 patients with serious viral acute respiratory distress syndrome
NY Times
DECEMBER 12, 2020
Distributing supplies is a daunting logistical challenge, involving sophisticated tracking equipment, military contingencies and tight security.
pharmaphorum
DECEMBER 13, 2020
Alexion has routinely featured among lists of top biopharma takeover prospects in the last couple of years, and that was a good call – AstraZeneca has just swooped in with $39 billion cash-and-stock takeover offer. The deal – the largest in the pharma sector since the start of the pandemic – bolsters AZ’s immunology franchise with $4 billion blockbuster Soliris (eculizumab) and longer acting follow-up Ultomiris (ravulizumab), plus a pipeline of 11 drugs for rare and autoimmune diseases.
Outsourcing Pharma
DECEMBER 17, 2020
A leader from the clinical trial solutions firm talks about the drive toward conducting trials without sites, and why that idea might lead to problems.
Pharma Times
DECEMBER 18, 2020
Danish pharma is seeking approval for drug as a weight management therapy
NY Times
DECEMBER 18, 2020
The Food and Drug Administration authorized a second coronavirus vaccine for emergency use, clearing the way for millions more Americans to be immunized next week.
pharmaphorum
DECEMBER 14, 2020
Daiichi Sankyo and AstraZeneca could be just weeks away from an EU approval for their antibody-drug conjugate (ADC) for breast cancer – Enhertu – which is tipped to become a multibillion-dollar blockbuster. At its meeting last week, the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of Enhertu (trastuzumab deruxtecan) for patients with unresectable or metastatic HER2-positive breast cancer, who have been previously treated with other anti-HER2 drugs.
Outsourcing Pharma
DECEMBER 16, 2020
Experts from a variety of research and drug development organizations share their thoughts on highlights from 2020, and predict what 2021 might hold.
Pharma Times
DECEMBER 15, 2020
The Russian Direct Investment Fund has released a new analysis of data obtained 21 days after administering the first dose of the vaccine, showing efficacy of 91.
NY Times
DECEMBER 17, 2020
An advisory group’s recommendation will mean millions more Americans can be inoculated, extending protection against Covid beyond major urban areas into rural and suburban regions.
pharmaphorum
DECEMBER 14, 2020
The roll-out of the biggest vaccination programme in the history of the UK’s NHS is gathering pace, as family doctors and their teams begin taking delivery of Pfizer/BioNTech’s COVID-19 shot. In a statement the NHS said that GP practices in more than 100 parts of the country are taking delivery of the vaccine today. Some clinics will begin immunisations this afternoon and the majority will start tomorrow (Tuesday), the NHS said.
Outsourcing Pharma
DECEMBER 14, 2020
The research (conducted by trial tech provider Litmus Health) shows an indepth picture of wearable device use, top devices, data capture and other factors.
Pharma Times
DECEMBER 17, 2020
French biotech will test vaccine candidate on 150 volunteers across four sites
NY Times
DECEMBER 18, 2020
Four people so far have had allergic reactions after getting the Pfizer-BioNTech vaccine. Experts say that shouldn’t deter most people from getting a jab.
pharmaphorum
DECEMBER 18, 2020
Researchers in the UK have developed a chatbot-enabled website that can train people to detect and counter misinformation on COVID-19 and other topics, using techniques from some of philosophy’s greatest critical thinkers. Earlier this year, the World Health organisation (WHO) said the world was dealing with an “infodemic” that is accompanying the pandemic and it is hard for the general public to recognise the “grey area of” misinformation.
Outsourcing Pharma
DECEMBER 16, 2020
William Carson says while the past year was full of challenges, embracing AI and other advanced technology led to impressive progress and opportunity.
Pharma Times
DECEMBER 16, 2020
New company will focus on developing bispecific antibodies for rare bleeding disorders
NY Times
DECEMBER 17, 2020
Heroic work went into the development of the coronavirus vaccines. But that doesn’t mean this industry deserves your affection.
pharmaphorum
DECEMBER 17, 2020
UK-based EUSA Pharma has begun a late-stage trial of its antibody siltuximab in COVID-19, hoping that the IL-6 inhibitor will succeed where class rivals from Roche and Sanofi/Regeneron have failed. Hertfordshire-based EUSA said recruitment has begun in phase 3 trial involving patients with COVID-19 previously treated with corticosteroids and other respiratory viruses associated with serious respiratory complications.
Outsourcing Pharma
DECEMBER 15, 2020
The newly formed group seeks to bring together research professionals to accelerate adoption and introduce industry standards in virtual and hybrid trials.
Pharma Times
DECEMBER 18, 2020
British pharma company also announces strategic collaboration agreement
NY Times
DECEMBER 17, 2020
The smaller number of expected doses, which appeared to be the result of a scheduling hiccup, reignited tensions between the federal government and Pfizer over vaccine supply.
pharmaphorum
DECEMBER 17, 2020
Trials of a fifth COVID-19 vaccine have begun in the UK, as IT issues threaten to delay the roll-out of the shot from Pfizer/BioNTech. France’s Valneva begun the phase 1/2 clinical study of the inactivated vaccine candidate VLA2001 in sites across the UK, supported by the National Institute for Health Research (NIHR). It is the first publicly announced inactivated COVID-19 vaccine candidate to begin clinical development in Europe.
Outsourcing Pharma
DECEMBER 16, 2020
A representative from the small-molecule solutions company explains how the ever-increasing mountain of life-sciences data has impacted drug development.
Expert insights. Personalized for you.
158 
Let's personalize your content